Chemoradiotherapy effcacy in squamous cell rectal cancer: a propensity score matched analysis

Introduction. Sporadic cases of squamous cell carcinoma of the rectum (rSCC) do not allow a comparative characterization of tumor aggressiveness and its response to chemoradiotherapy in relation to more common squamous cell entities, in particular, anal squamous cell carcinoma (aSCC).
Objective: comparative evaluation of the short- and long-term results of chemoradiation therapy in patients with rSCC and aSCC.
Material and Methods. In this retrospective study we included patients with nonmetastatic squamous cell carcinoma of the rectum (rSCC) and anal canal squamous cell carcinoma (aSCC) who received chemoradiotherapy and compared them in a 1:1 ratio using propensity-score matching. The dynamics of tumor response to treatment were compared by Kaplan-Meier survival analysis (OS and RFS) followed by Log-Rank verifcation, rate of complete response after 6 months.
Results. A total of 15 pairs of matched patients were evaluated. Patients in both groups had reliably similar sex, age, histological grade, initial primary tumor size, differing only in tumor histological subtype. In the aSCC group, 60 % of patients had metastases to pelvic lymph nodes, while in the rSCC group metastases had 46.67 % (p=1). The median follow-up was 44 months. The 3-year OS in the aSCC group of patients was 76.9 %, and 71.4 % in the rSCC group (p=0.567). The 3-year DFS in the aSCC group was 66.7 %, and in the rSCC group 34.7 % (p=0.406). The rate of achieving complete clinical response to CRT after 6 months was 86.7 % for the aSCC group and only 46.7 % for the rSCC group (p=0.05). Organ-saving treatment was achieved in 93.3 % of aSCC patients and 73.3 % of rSCC patients (p=0.33).
Conclusion. Overall and recurrence-free survival rates were not signifcantly decreased for rSCC patients relative to aSCC patients. This indicates a similar course and prognosis in the two diseases, but rSCC is characterized by a signifcantly lower rate of complete response to treatment.

1. Astaras C., Bornand A., Koessler T. Squamous rectal carcinoma: a rare malignancy, literature review and management recommendations. ESMO Open. 2021; 6(4). doi: 10.1016/j.esmoop.2021.100180.

2. Sturgeon J.D., Crane C.H., Krishnan S., Minsky B.D., Skibber J.M., Rodriguez-Bigas M.A., Chang G.J., You Y.N., Eng C., Das P. Defnitive Chemoradiation for Squamous Cell Carcinoma of the Rectum. Am J Clin Oncol. 2017; 40(2): 163–6. doi: 10.1097/COC.0000000000000126.

3. Malakhov N., Kim J.K., Adedoyin P., Albert A., Schreiber D., Lee A. Patterns of Care and Outcomes of Low-Lying Adenocarcinoma and Squamous Cell Carcinoma of the Rectum. J Gastrointest Cancer. 2022; 53(1): 105–12. doi: 10.1007/s12029-020-00552-3.

4. Clinical Guidelines “Rectal Cancer”. М., 2022. 78 p. (in Russian).

5. Guerra G.R., Kong C.H., Warrier S.K., Lynch A.C., Heriot A.G., Ngan S.Y. Primary squamous cell carcinoma of the rectum: An update and implications for treatment. World J Gastrointest Surg. 2016; 8(3): 252–65. doi: 10.4240/wjgs.v8.i3.252.

6. Dudaev Z.A., Khudoerov D.K., Mamedli Z.Z., Aliev V.A., Gordeev S.S., Myshlyakov V.S. “Watch and wait” strategy (active dynamic follow-up) in the management of rectal cancer patients with a complete clinical response. Pelvic Surgery and Oncology. 2022; 12(1): 35–40. (in Russian). doi: 10.17650/2686-9594-2022-12-1-35-40.

7. Dudaev Z.A., Khudoerov D.K., Mamedli Z.Z., Aliev V.A., Gordeev S.S., Magarramova Z.N. Short-term and long-term treatment outcomes in patients with lower and middle rectal cancer with complete clinical and pathomorphological response after comprehensive treatment. Pelvic Surgery and Oncology. 2022; 12(1): 41–8. (in Russian). doi: 10.17650/2686-9594-2022-12-1-41-48.

8. Dyson T., Draganov P.V. Squamous cell cancer of the rectum. World J Gastroenterol. 2009; 15(35): 4380–6. doi: 10.3748/wjg.15.4380.

9. Jeong B.G., Kim D.Y., Kim S.Y. Concurrent chemoradiotherapy for squamous cell carcinoma of the rectum. Hepatogastroenterology. 2013; 60(123): 512–6. doi: 10.5754/hge11293.

10. Dutta S.W., Alonso C.E., Waddle M.R., Khandelwal S.R., Janowski E.M., Trifletti D.M. Squamous cell carcinoma of the rectum: Practice trends and patient survival. Cancer Med. 2018; 7(12): 6093–103. doi: 10.1002/cam4.1893.

11. Musio D., De Felice F., Manfrida S., Balducci M., Meldolesi E., Gravina G.L., Tombolini V., Valentini V. Squamous cell carcinoma of the rectum: The treatment paradigm. Eur J Surg Oncol. 2015; 41(8): 1054–8. doi: 10.1016/j.ejso.2015.03.239.

12. Glynne-Jones R., Sebag-Montefore D., Meadows H.M., Cunningham D., Begum R., Adab F., Benstead K., Harte R.J., Stewart J., Beare S., Hackshaw A., Kadalayil L.; ACT II study group. Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial. Lancet Oncol. 2017; 18(3): 347–56. doi: 10.1016/S1470-2045(17)30071-2. Erratum in: Lancet Oncol. 2017; 18(4). Erratum in: Lancet Oncol. 2020; 21(11).

13. Id Said B., Buchan D., Liu Z., Kim J., Hosni A., Brierley J.D., Chadi S., Grant R.C., Kalimuthu S., Liu Z.A., Lukovic J. Demographics, pattern of practice and clinical outcomes in rectal squamous cell carcinoma. Colorectal Dis. 2023; 25(4): 608–15. doi: 10.1111/codi.16417.

14. Loganadane G., Servagi-Vernat S., Schernberg A., Schlienger M., Touboul E., Bosset J.F., Huguet F. Chemoradiation in rectal squamous cell carcinoma: Bi-institutional case series. Eur J Cancer. 2016; 58: 83–9. doi: 10.1016/j.ejca.2016.02.005.

15. Péron J., Bylicki O., Laude C., Martel-Lafay I., Carrie C., Racadot S. Nonoperative management of squamous-cell carcinoma of the rectum. Dis Colon Rectum. 2015; 58(1): 60–4. doi: 10.1097/DCR.0000000000000218.

16. Steinemann D.C., Müller P.C., Billeter A.T., Bruckner T., Ulrich A., Müller-Stich B.P. Surgery is essential in squamous cell cancer of the rectum. Langenbecks Arch Surg. 2017; 402(7): 1055–62. doi: 10.1007/s00423-017-1614-5.

17. Yang Y., Yu J., Hu J., Zhou C., Niu J., Ma H., Han J., Fan S., Liu Y., Zhao Y., Zhao L., Wang G. A systematic and comprehensive analysis of colorectal squamous cell carcinoma: Implication for diagnosis and treatment. Cancer Med. 2022; 11(12): 2492–502. doi: 10.1002/cam4.4616.

18. Astaras C., De Vito C., Chaskar P., Bornand A., Khanfr K., Sciarra A., Letovanec I., Corro C., Dietrich P.Y., Tsantoulis P., Koessler T. The frst comprehensive genomic characterization of rectal squamous cell carcinoma. J Gastroenterol. 2023; 58(2): 125–34. doi: 10.1007/s00535-022-01937-w.

19. Daling J.R., Madeleine M.M., Johnson L.G., Schwartz S.M., Shera K.A., Wurscher M.A., Carter J.J., Porter P.L., Galloway D.A., McDougall J.K. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer. 2004; 101(2): 270–80. doi: 10.1002/cncr.20365.

20. Alemany L., Saunier M., Alvarado-Cabrero I., Quirós B., Salmeron J., Shin H.R., Pirog E.C., Guimerà N., Hernandez-Suarez G., Felix A., Clavero O., Lloveras B., Kasamatsu E., Goodman M.T., Hernandez B.Y., Laco J., Tinoco L., Geraets D.T., Lynch C.F., Mandys V., Poljak M., Jach R., Verge J., Clavel C., Ndiaye C., Klaustermeier J., Cubilla A., Castellsagué X., Bravo I.G., Pawlita M., Quint W.G., Muñoz N., Bosch F.X., de Sanjosé S.; HPV VVAP Study Group. Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int J Cancer. 2015; 136(1): 98–107. doi: 10.1002/ijc.28963.

21. André F., Ciruelos E.M., Juric D., Loibl S., Campone M., Mayer I.A., Rubovszky G., Yamashita T., Kaufman B., Lu Y.S., Inoue K., Pápai Z., Takahashi M., Ghaznawi F., Mills D., Kaper M., Miller M., Conte P.F., Iwata H., Rugo H.S. Alpelisib plus fulvestrant for PIK3CAmutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: fnal overall survival results from SOLAR-1. Ann Oncol. 2021; 32(2): 208–17. doi: 10.1016/j.annonc.2020.11.011.

22. Kalinsky K., Hong F., McCourt C.K., Sachdev J.C., Mitchell E.P., Zwiebel J.A., Doyle L.A., McShane L.M., Li S., Gray R.J., Rubinstein L.V., Patton D., Williams P.M., Hamilton S.R., Conley B.A., O'Dwyer P.J., Harris L.N., Arteaga C.L., Chen A.P., Flaherty K.T. Efect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial. JAMA Oncol. 2021; 7(2): 271–8. doi: 10.1001/jamaoncol.2020.6741. Erratum in: JAMA Oncol. 2021.

23. Yap T.A., Tan D.S.P., Terbuch A., Caldwell R., Guo C., Goh B.C., Heong V., Haris N.R.M., Bashir S., Drew Y., Hong D.S., Meric-Bernstam F., Wilkinson G., Hreiki J., Wengner A.M., Bladt F., Schlicker A., Ludwig M., Zhou Y., Liu L., Bordia S., Plummer R., Lagkadinou E., de Bono J.S. Firstin-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors. Cancer Discov. 2021; 11(1): 80–91. doi: 10.1158/2159-8290.CD-20-0868.